Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

273

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
ObesityOverweight
Interventions
DRUG

AC2307

subcutaneous, twice daily, low dose

DRUG

placebo

subcutaneous, twice daily, low dose

DRUG

AC2307

subcutaneous, twice daily, middle dose

DRUG

placebo

subcutaneous, twice daily, middle dose

DRUG

AC2307

subcutaneous, twice daily, high dose

DRUG

placebo

subcutaneous, twice daily, high dose

Trial Locations (18)

Unknown

Research Site, Birmingham

Research Site, Chandler

Research Site, Santa Rosa

Research Site, Walnut Creek

Research Site, Denver

Research Site, Jacksonville

Research Site, Miami

Research Site, Chicago

Research Site, Overland Park

Research Site, Baton Rouge

Research Site, Butte

Research Site, Cincinnati

Research Site, Eugene

Research Site, Medford

Research Site, Greer

Research Site, Mt. Pleasant

Research Site, Austin

Research Site, Olympia

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY